Table 2.
Tumor response
| Variable | GEM (n=47) | GEM-T (n=44) | GEM-X (n=33) |
|---|---|---|---|
| Objective response rate | |||
| Partial response | 6 (12.7) | 7 (15.9) | 7(21.2) |
| Stable disease | 24 (51) | 19 (43.1) | 17 (47.2) |
| Progressive disease | 17 (36.1) | 18 (40.1) | 9 (27.3) |
| Disease control rate | 30 (63.8) | 26 (59.1) | 24 (72.7) |
| Treatment duration (wk) | 17 | 10.4 | 22.8 |
| 95% CI | 10.6-23.3 | 7.7-13.0 | 12.7-32.9 |
Values are presented as number (%). GEM, gemcitabine; GEM-T, gemcitabine plus erlotinib; GEM-X, gemcitabine plus capecitabine; CI, confidence interval.